Table 3.
Target-to-background ratios of 89Zr-DFO-6E11 determined by ex vivo biodistribution 144 h post-injection in HCC827 tumour-bearing mice (N = 3/dose)
| Tumour/blood | Tumour/muscle | Spleen/blood | Spleen/muscle | |
|---|---|---|---|---|
| + 0 μg | 9.01 ± 1.82 | 1.25 ± 0.05 | 345.11 ± 34.65 | 56.61 ± 13.87 |
| + 10 μg | 25.43 ± 4.00 | 7.28 ± 2.40 | 244.01 ± 100.9 | 47.26 ± 5.68 |
| + 30 μg | 41.94 ± 1.84 | 10.74 ± 1.49 | 140.62 ± 15.58 | 34.69 ± 3.09 |
| + 100 μg | 14.05 ± 4.70 | 17.23 ± 3.09 | 21.65 ± 8.47 | 24.75 ± 5.25 |
| + 500 μg | 1.80 ± 0.33 | 10.34 ± 3.50 | 1.98 ± 0.37 | 11.20 ± 3.76 |
Values are mean ± SEM